Affinia Therapeutics receives FDA orphan drug designation for AFTX-201
AFTX-201 is an investigational gene therapy delivered through a single intravenous infusion.
Drug Development
Evogene and ELEO to develop new oral PCSK9 inhibitors
Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH
Cellares and Papillon partner for PPL-001 manufacturing automation
EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168
Halozyme and Incyte sign licence agreement for INCA033989 formulations
Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Aptar unveils framework for injectable drug delivery systems
